objeCtives: There are challenges to assess the current situation of health care organizations' waste management by the level and to formulate methods for further improvement. Thus, purpose of this assessment study was to formulate reference about methods to improve current situation of health care organizations' waste management. Methods: Study was done by the descriptive method among 39 health care organizations using study forms, as questionnaires, checklist and tests. Results: In Ulaanbaatar waste disposal company is 100% responsible for hazardous waste of health care organizations, but 50% of domestic waste are taken care by hospitals themselves. However, in rural areas 48.7-64% of hospitals and 57.1% of health care centers are responsible for both their domestic and hazardous waste. 50% of hospitals drain the liquid waste into main sewage and liquid waste from laboratory are drained into central sewage after disinfection. Waste management team works in 66.7% of hospitals, and nurses and dry-nurses are responsible in collecting of waste in 97.4% of hospitals. The team consists of 1-3 people in 50% of hospitals, 4-6 people in 39.5% of hospitals but more people in tertiary level hospitals. ConClusions: Legal documents about waste management of health care organizations are approved; most secondary and tertiary level health care organizations have workers responsible for waste. They have developed plans to improve the "Waste management" and installed waste registration system. Despite setting up the temporary storages at hospitals and health care centers, they still need improvement. Although any equipment with mercury has been prohibited to use in health care organizations, 50% of hospitals are still using and it has been difficult to collect, transport and dispose mercury containing waste. objeCtives: This study is designed to review and to compare the concept and content of market access in both western and Chinese pharmaceutical environments, and further endeavor to clarify the responsibilities of each stakeholder in China to help providing better drug accessibility and affordability for the people. Methods: A literature review was undertaken to understand comprehensively the current market access protocols in mature markets as well as in China. Industry interviews, consulting surveys and data analysis were also conducted to collect first-hand data for comparison. Results: Unlike developed countries, where drug market access includes reimbursement and lots of patient access schemes, the market access of pharmaceuticals in China has a much broader scope, ranging from pricing, reimbursement, tendering, to hospital listing, etc, which indicates drug market access in China is a highly fragmented process and involves a lot of different government departments. The centralized government management style, a historical consequence of the transformation from planned economy to market economy, is most attributable to this phenomenon. As a result, civil society, such as NGOs and academic institutions are relatively weaker compared to western countries, and they are not able to take intrinsically influential roles during market access decision-making process. This further leads to a high administration-oriented and low market-oriented drug market access present circumstance. Consequently, the timeline of drug market access in China is much longer than that of the mature market. ConClusions: The definition of market access in China needs to be redefined and global perspectives shall be incorporated. A re-structured concept will better serve China's changing environment. objeCtives: Even the Ministry of Health is taking its attention to improve quality and safety of medical services, developing and implementing relevant policy and directions, quantity of complaints and occupational mistakes coming from citizens for medical services are still not going down. Therefore it is very necessary for every health organizations to analyze the situation. Methods: To study processes for evidences and requirements of quality, information is collected by quantitave method and the cross sectional survey form was used. Results: On the service standard surveys taken from medical staffs, 56.6% in I level hospitals, 50.0% in II level hospitals and 73.3% in III level hospitals are replied as they follow certain standards for their services. But respondents replied as 47.4% of the standards for medical services, which is the most percent, are not incompatible for wards. When summarizing the results, we can say it is not clear what service standards the medical staffs cared for by the full-time intensivists had a shorter RCC and ventilator days, lower expenses and RCC transfer rates (p < 0.001), and higher weaning and complication rates (p < 0.05) than those cared for by the part-time and full-time responsible chest physicians. Risk factors for mortality variables including APACHE II, transfer to the ICU, RCC length of stays, and albumin level. APACHE II, types of physicians staffed, transfer to the ICU, RCC length of stays, and Creatinine were the risk factors affecting weaning rates in the RCC patients. ConClusions: There were differences in the overall use of health care resources and weaning rates among the patients cared for by full-time intensivitsts, part-time responsible chest physicians, and full-time responsible chest physicians but no difference in adjusting mortality. To study labels of selected Nutraceutical products from health care market. Methods: For objective first we have studied the regulations made by FDA of India regarding Nutraceuticals labeling requirement, for which we have used secondary data collection method. For second objective we have collected 30 samples randomly from Nutraceutical segments from local Pharmacies and studied the labels carefully. Results: The follow-up by Nutrceuticals manufacturer to labeling regulations found very moderate in our study. We found that regulations about list of ingredients, nutritional value, declaration regarding veg non-veg, declaration regarding food additives and other crucial parts of label are poorly followed by Nutraceutical Manufacturer in India. ConClusions: As we have studied the regulations regarding labeling of Nutraceuticals, we found that this regulations are sufficient and appropriate. Again through this research work we come to make this conclusion that Nutraceutical manufacturer/importer in India are not that much serious regarding labeling which is threatening in some aspects so they used to make mistakes in labeling knowingly or unknowingly.
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objeCtives: To develop a method of setting a Drug Price Reference Index (DPRI) in the Philippines to ensure good value for money in the procurement and reimbursement of essential medicines. Methods: A database of prevailing drug procurement prices was created from actual purchase orders submitted in 2012 by government procuring entities in the Philippines. The database includes information on the unit cost, volumes of procurement, source/supplier/manufacturer, brand, mode of procurement and location of the hospital for each formulation and strength of all drugs in the National Formulary. Univariate regression analyses were performed for commonly sourced essential drugs exploring possible determinants of drug costs, which include quantities procured and hospital bed capacity. Further costcomparisons were made for other potential determinants such as mode of procurement, supplier/manufacturer and distance of distribution. Results: Price data was analyzed for 20 drug products with the highest share of procurement in terms of volume and value. Extreme wide variations in unit costs were consistently observed for all drugs analyzed. The price differentials, i. e. high/low ratio, was found to be up to 60 times when comparing the highest to the lowest priced drugs. The variations in prices were not associated by volumes procured, distance of distribution and hospital bed capacity. Suppliers were also observed to charge different prices for the same brands to different public hospitals, indicating information asymmetry on reasonable prices of drugs. ConClusions: Based on the observed wide variations in drug procurement prices in the Philippines, setting the DPRI at the median value for most drugs was found to be an appropriate method to set ceiling prices for public sector procurement. For monopolized pharmaceutical products, other methods may be more appropriate such as value-based pricing, price negotiations and external reference pricing to relevant countries.
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